Serum Institute-ICMR finish enrollment of participants for phase 3 trial of Covid-19 vaccine

SII has already manufactured 40 million doses of the vaccine, under the at-risk manufacturing and stockpiling license from DCGI, the company said. The joint trial has been funded by ICMR, while SII has funded other expenses for the vaccine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3lpsku7
via IFTTT